{"organizations": [], "uuid": "ef1d582a0c803dfe01f0fa2b533db63e76ad5623", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-foundation-medicine-enters-into-am/brief-foundation-medicine-enters-into-amended-and-restated-ex-us-commercialization-agreement-with-f-hoffmann-la-roche-ltd-idUSFWN1QN0R1", "country": "US", "domain_rank": 408, "title": "BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.987, "site_type": "news", "published": "2018-03-06T05:47:00.000+02:00", "replies_count": 0, "uuid": "ef1d582a0c803dfe01f0fa2b533db63e76ad5623"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-foundation-medicine-enters-into-am/brief-foundation-medicine-enters-into-amended-and-restated-ex-us-commercialization-agreement-with-f-hoffmann-la-roche-ltd-idUSFWN1QN0R1", "ord_in_thread": 0, "title": "BRIEF-Foundation Medicine Enters Into Amended And Restated Ex-US Commercialization Agreement With F. Hoffmann-La Roche Ltd", "locations": [], "entities": {"persons": [{"name": "f. hoffmann-la roche", "sentiment": "none"}, {"name": "roche", "sentiment": "none"}], "locations": [], "organizations": [{"name": "f. hoffmann-la roche ltd", "sentiment": "negative"}, {"name": "reuters) - foundation medicine inc", "sentiment": "neutral"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Foundation Medicine Inc:\n* FOUNDATION MEDICINE SAYS ON FEB 28, CO ENTERED INTO AMENDED AND RESTATED EX-US COMMERCIALIZATION AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD - SEC FILING\n* FOUNDATION MEDICINE INC - AGREEMENT AMENDS AND RESTATES THAT CERTAIN EX-US COMMERCIALIZATION AGREEMENT, EFFECTIVE AS OF APRIL 7, 2015\n* FOUNDATION MEDICINE- PER AGREEMENT, ROCHE HAS EXCLUSIVE RIGHT IN TERRITORY TO COMMERCIALIZE COâ€™S CLINICAL DIAGNOSTIC TESTING COMMERCIAL PRODUCTS\n* FOUNDATION MEDICINE INC - INITIAL TERM OF AGREEMENT EXPIRES ON APRIL 7, 2020 AND MAY BE EXTENDED BY ROCHE FOR ADDITIONAL TWO-YEAR PERIODS Source text ( bit.ly/2FiMt07 ) Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2FiMt07"], "published": "2018-03-06T05:47:00.000+02:00", "crawled": "2018-03-06T22:29:01.020+02:00", "highlightTitle": ""}